Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
about
Pancreatic cancer: pathogenesis, prevention and treatmentAnti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algaeSmall molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapyThe multiple facets of drug resistance: one history, different approaches.Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer.Targeted therapies for pancreatic cancer.Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signalingThe Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cellsCurrent knowledge on pancreatic cancer.Apoptotic pathways in pancreatic ductal adenocarcinomaNF-kappaB signaling pathway and its therapeutic implications in human diseases.Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer.Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathwayEpigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.L1 cell adhesion molecule as a therapeutic target in cancer.18F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models.A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1.Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid.Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin.Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines.Nuclear factor κB is a key transcription factor in the duodenal contractility alterations induced by lipopolysaccharide.Solute carrier transporters: potential targets for digestive system neoplasms.
P2860
Q24670990-5B8BADB8-7793-4908-8265-E958488FA8ECQ28486199-00FEFA61-B1DF-4BE6-A99B-100E520230B6Q33227187-D41DEEBF-FB6B-4A73-9F95-BA047928B981Q33437264-D4DD5E79-E20C-450B-9B54-BF22519F9D91Q33697116-489ABFD0-DBF0-4D5D-9E8E-A57B16B36BF5Q33894596-460CA968-F208-4EF1-A682-6BE03EDF8704Q33899923-14CEF693-2EAF-4905-B77D-7A95384B74FAQ34305783-998F4880-5A4E-477C-A683-FD48D1E4CDB3Q34690409-359B5FE3-2392-4403-8E57-4E27D0883F5AQ35486194-C3D6C1FB-6FA7-46EC-A68A-E9F6483DABFCQ35971808-E49E5A2C-E8B3-4432-8FBE-7D80C63E8EC0Q36835642-1DE58F35-77CD-441F-A203-DB8DB551A11BQ37293337-0E99499F-1CDB-4C36-A3E3-CD09EB1961F3Q37348076-0689EDFD-E011-41D8-86C4-82211F6B83F6Q37488862-999FDD00-D81C-4D6E-ABE1-71664BF9EE4DQ37853945-F3BE92CE-026C-4907-908F-A80A3642AD05Q38701631-0D08176B-1095-4DB2-A07C-E56EADA2E501Q38735688-4B1B4E1D-6F7A-4FAA-9340-A2CDACD1B393Q38953653-61D5A562-A2D0-4494-B06A-867A8440A575Q39020120-5ABE987F-1BB7-4891-BEDF-F2659864DCDEQ39344030-DBFAB510-AC77-4451-B234-373BD828FE1BQ39670791-1C83B087-1BE5-4009-A62C-7189E5657C52Q40159774-357311C0-5ADD-403C-8D38-675BAA630A93Q40419711-4222758F-C883-47E5-857B-07BE9B5B66C3Q42727071-AAD9D99C-C966-4B59-A0E6-1AC1D64742D7Q49667930-6C0A3DA4-E792-4695-8773-6A4849F9B05C
P2860
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@en
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@nl
type
label
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@en
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@nl
prefLabel
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@en
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@nl
P2093
P2860
P356
P1476
Usage of the NF-kappaB inhibit ...... otherapy of pancreatic cancer.
@en
P2093
André Gehrz
Christina March
Frauke Grohmann
Heiner Schäfer
Holger Kalthoff
Kai Wegehenkel
Maike Witt
Sieglinde Haye
Susanne Müerköster
Ulrich R Fölsch
P2860
P304
P356
10.1002/IJC.10963
P577
2003-04-01T00:00:00Z